Supplementary Figure S10 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

Key Points

The immunofluorescence staining revealed the presence of CD8, CD4, and FoxP3 T cells within tumors.
A notable presence of T cells indicates potential immune activation in patients receiving durvalumab and tremelimumab.
Trial results may guide future treatment strategies for head and neck squamous cell carcinoma.
Further analysis is required to understand the implications of T cell infiltration in patient outcomes.

Open-label trial assesses T cell responses in head and neck squamous cell carcinoma, suggesting potential immunotherapy benefits.

No abstract yet. The journal hasn't published one we can show.

No takes yet. Share an insight, caveat, or question.

Kim et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share